ARiDA
ARiDA

Blog

Where science enters the biopharma decision.

Essays and operating notes on the methods behind target, asset, indication, valuation and portfolio choices. Each reviewed article names the sources used and the conditions that limit the conclusion.

Decision ScienceDecision MethodsSystem Design
Category framing

Decision Science

Essays about the missing computational layer between scientific insight and biopharma business decisions.

April 23, 20267 min read

Why fluent answers are not enough for biotech decisions

The hard part is preserving evidence type, uncertainty and decision consequence long enough for expert review.

  • Scientific evidence has different meanings and failure modes.
  • The model must show how a finding changes a calculation or gate.
  • A reviewer needs the case beneath the recommendation.
Read piece
April 21, 20266 min read

Build the decision case before the committee deck

A committee document is credible only when the evidence, assumptions and alternatives exist underneath it.

  • Begin with the decision and its reversal conditions.
  • Compute the case before writing the narrative.
  • Preserve alternatives, dissent and approvals.
Read piece
April 19, 20267 min read

What a decision system must prove inside pharma

Enterprise usefulness depends on method, review and continuity across scientific and business functions.

  • Test one live decision, not a generic prompt.
  • Separate evidence rights from analytical authority.
  • Require an inspectable release process.
Read piece
April 17, 20267 min read

The missing layer between scientific systems and business models

Biopharma teams still move critical assumptions by hand between evidence tools and financial models.

  • Scientific platforms organize evidence.
  • Business models often begin with manual scientific assumptions.
  • ARiDA supplies the computation between them.
Read piece
April 15, 20266 min read

Parallel work matters only when the decision record survives

Specialists can divide a complex review, but the result needs one controlled case and a clear release state.

  • Division of work is an implementation choice.
  • Collected evidence needs a shared decision frame.
  • Files and approvals must outlast the run.
Read piece
Operator notes

Decision Methods

Practical notes on the evidence, calculations and review conditions behind recurring biopharma decisions.

April 13, 20267 min read

Run a competitive landscape around a decision, not a company list

A useful landscape explains which competitor changes the target profile, timing or investment case.

  • Define the decision and comparator rule first.
  • Preserve registry dates and status changes.
  • Translate observations into explicit scenarios.
Read piece
April 11, 20268 min read

Evaluate indication expansion without hiding the weak dimension

Rank biology, clinical feasibility and economics while keeping hard gates and missing evidence separate.

  • Resolve the indication and patient segment first.
  • Use criteria that match the decision archetype.
  • Do not fabricate economics to complete a ranking.
Read piece
April 9, 20268 min read

Triage a portfolio without turning judgment into a score

Use hard gates, uncertainty and resource constraints to expose the real allocation choice.

  • Separate eligibility from ranking.
  • Model shared scientific risk.
  • Record the action and reversal condition.
Read piece
April 7, 20269 min read

Build a biotech valuation case that exposes its science

A credible valuation connects scientific support, uncertainty and commercial assumptions to the value distribution.

  • Treat PoS as an inspectable assumption.
  • Use distributions when the case is uncertain.
  • Show what evidence would change value.
Read piece
April 5, 20267 min read

Build an evidence review that another scientist can audit

Protocol, screening decisions and evidence tables matter more than a polished narrative.

  • Write the protocol before searching.
  • Keep exclusions and contradictions visible.
  • Link each conclusion to included evidence.
Read piece
April 3, 20266 min read

Monitor clinical trial changes without confusing updates with events

Preserve registry timestamps, field-level differences and materiality rules before escalating a signal.

  • Store the prior record and retrieval time.
  • Compare material fields, not page text.
  • Tie alerts to a decision case.
Read piece
April 1, 20267 min read

Turn a regulatory question into a bounded strategy brief

Use current authority, jurisdiction and product context, then separate text from strategic interpretation.

  • Define jurisdiction, product and decision date.
  • Prefer current primary authority.
  • State where counsel or agency interaction is required.
Read piece
Technical review

System Design

Architecture notes for teams evaluating whether computation, decision records and enterprise controls hold together in production.

March 30, 20266 min read

Why durable state matters in a long scientific review

The system must preserve plans, files and accepted decisions across turns and interruptions.

  • Conversation text is not enough state.
  • Checkpoints need a clear source of truth.
  • Continuation should not reconstruct accepted work.
Read piece
March 28, 20266 min read

How parallel specialists should return work to one case

A shared brief, file-backed outputs and collection gates keep divided work coherent.

  • Dispatch from one decision frame.
  • Return artifacts with provenance.
  • Validate before synthesis.
Read piece
March 26, 20268 min read

Combine scientific data and code without erasing provenance

Acquisition, normalization and computation need separate records inside the same decision case.

  • Keep acquisition separate from computation.
  • Record identifiers, versions and retrieval time.
  • Release the method with the result.
Read piece
March 24, 20267 min read

Auditability is a chain of records, not a citation count

A reviewer needs to trace the question, source, transformation, assumption, result and release state.

  • Citations establish origin, not correctness.
  • Transformations and assumptions need identity.
  • Release state belongs in the audit trail.
Read piece
March 22, 20266 min read

Why committee outputs need a computation record

The memo should summarize an inspectable case, not substitute for one.

  • The document is downstream of the method.
  • Reviewers need scenarios and unresolved gaps.
  • A new event should reopen the same case.
Read piece
March 20, 20268 min read

Design scientific decision systems around methods, not prompts

Stable calculators, evidence contracts and explicit gates should carry repeatable parts of the work.

  • Use language models where interpretation is required.
  • Use deterministic methods where repeatability matters.
  • Make every handoff explicit.
Read piece